Clinical Pharmacokinetics

, Volume 18, Issue 6, pp 472–484 | Cite as

Pharmacokinetic Drug Interactions with Oral Contraceptives

  • David J. Back
  • Michael L’E. Orme
Pharmacokinetic Drug Interactions

Summary

Oral contraceptive steroids are used by an estimated 60 to 70 million women worldwide. Over the past 20 years there have been both case reports and clinical studies on the topic of drug interactions with these agents. Some of the interactions are of definite therapeutic relevance, whereas others can be discounted as being of no clinical significance. Pharmacological interactions between oral contraceptive steroids and other compounds may be of 2 kinds: (a) drugs may impair the efficacy of oral contraceptive steroids, leading to breakthrough bleeding and pregnancy (in a few cases, the activity of the contraceptive is enhanced); (b) oral contraceptive steroids may interfere with the metabolism of other drugs.

A number of anticonvulsants (phenobarbital, Phenytoin, carbamazepine) are enzymeinducing agents and thereby increase the clearance of the oral contraceptive steroids. Valproic acid has no enzyme-inducing properties, and thus women on this anticonvulsant can rely on their low dose oral contraceptive steroids for contraceptive protection. Researchers are now beginning to unravel the molecular basis of this interaction, with evidence of specific forms of cytochrome P450 (P450IIC and IIIA gene families) being induced by phenobarbital. Rifampicin, the antituberculous drug, also induces a cytochrome P450 which is a product of the P450IIIA gene subfamily. This isozyme is one of the major forms involved in 2-hydroxylation of ethinylestradiol.

Broad spectrum antibiotics have been implicated in causing pill failure; case reports document the interaction, and general practitioners are convinced that it is real. The problem remains that there is still no firm clinical pharmacokinetic evidence which indicates that blood concentrations of oral contraceptive steroids are altered by antibiotics. However, perhaps this should not be a surprise, given that the incidence of the interaction may be very low. It is suggested that an individual at risk will have a low bioavailability of ethinylestradiol, a large enterohepatic recirculation and gut flora particularly susceptible to the antibiotic being used.

Two drugs, ascorbic acid (vitamin C) and paracetamol (acetaminophen), give rise to increased blood concentrations of ethinylestradiol due to competition for sulphation. The interactions could have some significance to women on oral contraceptive steroids who regularly take high doses of either drug. Although on theoretical grounds adsorbents (e.g. magnesium trisilicate, aluminium hydroxide, activated charcoal and kaolin) could be expected to interfere with oral contraceptive efficacy, there is no firm evidence that this is the case. Similarly, there is no evidence that smoking alters the pharmacokinetics of oral contraceptive steroids.

These agents are now well documented as being able to alter the pharmacokinetics of other concomitantly administered drugs. The clearance of a number of benzodiaze-pines undergoing oxidation (chlordiazepoxide, alprazolam, diazepam) and nitro reduction (nitrazepam), theophylline, prednisolone, caffeine and cyclosporin, is reduced in oral contraceptive steroid users. The clearance of some drugs undergoing glucuronidation (temazepam, salicylic acid, paracetamol, morphine, clofibric acid) is apparently increased.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abernethy DR, Greenblatt DJ, Divoll M, Arendt R, Ochs HR, et al. Impairment of diazepam metabolism by low-dose estrogen-containing oral-contraceptive steroids. New England Journal of Medicine 306: 791–792, 1982PubMedCrossRefGoogle Scholar
  2. Abernethy DR, Greenblatt DJ, Ochs HR, Weyers D, Divoll M, et al. Lorazepam and oxazepam kinetics in women on lowdose contraceptives. Clinical Pharmacology and Therapeutics 33: 628–632, 1983PubMedCrossRefGoogle Scholar
  3. Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. European Journal of Clinical Pharmacology 28: 425–428, 1985PubMedCrossRefGoogle Scholar
  4. Back DJ, Bates M, Bowden M, Breckenridge AM, Hall MJ, et al. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 22: 495–503, 1980aPubMedCrossRefGoogle Scholar
  5. Back DJ, Bates M, Breckenridge AM, Crawford FE, Ellis A, et al. Metabolism by gastrointestinal mucosa-clinical aspects. In Prescott & Nimmo (Eds) Drug absorption, pp. 80–87, ADIS Press, Sydney, 1980bGoogle Scholar
  6. Back DJ, Bates M, Breckenridge AM, Ellis A, Maclver M, et al. The in vitro metabolism of elhinyloeslradiol, mestranol and levonorgestrel by human jejunal mucosa. British Journal of Clinical Pharmacology 11: 275–278, 1981aPubMedCrossRefGoogle Scholar
  7. Back DJ, Breckenridge AM, Crawford FE, Hall JM, Maclver M, et al. The effect of rifampicin on the pharmacokinetics of ethinyloestradiol in women. Contraception 21: 135–143, 1980cPubMedCrossRefGoogle Scholar
  8. Back DJ, Breckenridge AM, Crawford FE, Maclver M, Orme ML’E, et al. An investigation of the pharmacokinetics of ethinyleslradiol in women using radioimmunoassay. Contraception 20: 263–273, 1979aPubMedCrossRefGoogle Scholar
  9. Back DJ, Breckenridge AM, Crawford FE, Maclver M, Orme ML’E, et al. The effect of rifampicin on norethisterone pharmacokinelics. European Journal of Clinical Pharmacology 15: 193–197, 1979bPubMedCrossRefGoogle Scholar
  10. Back DJ, Breckenridge AM, Crawford FE, Maclver M, Orme ML’E, et al. Interindividual variation and drug interactions with hormonal steroid contraceptives. Drugs 21: 46–61, 1981bPubMedCrossRefGoogle Scholar
  11. Back DJ, Breckenridge AM, Cross KJ, Orme ML’E, Thomas E. An antibiotic interaction with ethinyloestradiol in the rat and rabbit. Journal of Steroid Biochemistry 16: 407–413, 1982aPubMedCrossRefGoogle Scholar
  12. Back DJ, Breckenridge AM, Maclver M, Orme ML’E. Purba HS, et al. The interaction of ethinyloestradiol with ascorbic acid in man. British Medical Journal 282: 1516, 1981cPubMedCrossRefGoogle Scholar
  13. Back DJ, Breckenridge AM, Maclver M, Orme ML’E, Purba HS, et al. The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans. British Journal of Clinical Pharmacology 13: 325–330, 1982bPubMedCrossRefGoogle Scholar
  14. Back DJ, Breckenridge AM, Maclver M, Orme ML’E, Rowe PH, et al. The effects of ampicillin on oral contraceptive steroids in women. British Journal of Clinical Pharmacology 14: 43–48, 1982cPubMedCrossRefGoogle Scholar
  15. Back DJ, Breckenridge AM, Orme ML’E. Drug interactions with oral contraceptives. International Planned Parenthood Federation 17: 1–2, 1983Google Scholar
  16. Back DJ, Grimmer SFM, Orme ML’E, Proudlove C, Mann RD, et al. Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. British Journal of Clinical Pharmacology 25: 527–532, 1988PubMedCrossRefGoogle Scholar
  17. Bacon JF, Shenfield GM. Pregnancy attributable to interaction between tetracycline and oral contraceptives. British Medical Journal 1: 293, 1980CrossRefGoogle Scholar
  18. Bainton R. Interaction between antibiotic therapy and contraceptive medication. Oral Surgery 61: 453–455, 1986CrossRefGoogle Scholar
  19. Ball SE, Forrester LM, Wolf CR, Back DJ. Differences in the cytochrome P450 isozymes involved in the 2-hydroxylation of estradiol and 17α-ethinyloestradiol: relative activities of rat and human liver enzymes. Biochemical Journal, in press, 1990Google Scholar
  20. Belaisch J, Driguez P, Janud A. Influence de certains medicaments sur l’action des pilules contraceptifs. Nouvelle Presse Médicale 5: 1645–1646, 1976PubMedGoogle Scholar
  21. Boehm FH, Di Pietro DL, Gross DA. The effect of ampicillin administration on urinary estriol and serum estradiol in the normal pregnant patient. American Journal of Obstetrics and Gynecology 119: 98–103, 1974PubMedGoogle Scholar
  22. Bockenoogcn SJ, Szcfler SJ, Jusko WJ. Prcdnisolone disposition and protein binding in oral contraceptive users. Journal of Clinical Endocrinology and Metabolism 56: 702–709, 1983CrossRefGoogle Scholar
  23. Chapman CR. Absorption and metabolism of steroid prodrugs. Ph. D Thesis. University of Liverpool. 1981Google Scholar
  24. Combalben J, Fahre I, Febre G, Dalet I, Deraneourl J, et al. Metabolism of cyclosporin A, IV. Purification and identification of the rifampicin-mduciblc human liver cytochrome P-450 (Cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metabolism and Disposition 17: 197–207, 1989Google Scholar
  25. Coulam CB, Anncgers JF. Do anliconv ulsants reduce the efficacy of oral contraceptives? Epilepsia 20: 519–526, 1979PubMedCrossRefGoogle Scholar
  26. Crawford FE, Back DJ, Orme ML’E, Breckenridge AM. Oral contraceptive steroid plasma concentrations in smokers and nonsmokers. British Medical Journal 282: 1829–1830, 1981PubMedCrossRefGoogle Scholar
  27. Crawford P, Chadwick D, Cleland P, Tjia J, Cowie A, et al. The lack of effect of sodium Nalproate on the pharmacokinetics ot oral contraceptive steroids. Contraception 33: 51–59, 1986CrossRefGoogle Scholar
  28. Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, et al. The interaction of Phenytoin and carbamazepine with combined oral contraceptives. British Journal of Clinical Pharmacology ((l/c))Google Scholar
  29. Denk H, Eckerstarfer R, Talcoll RE, Schenkman JB. Alteration of hepatic microsomal cnzymes by griseofulvin treatment of mice. Biochemical Pharmacology 26: 1125–1130, 1977PubMedCrossRefGoogle Scholar
  30. Deray G, Le Hoang P, Cacoub P, Assogba U, Grippon P, et al. Oral contraceptive interaction with cyclosporin. Lancel 1: 158–159, 1987CrossRefGoogle Scholar
  31. De Sano EA, Hurley SC. Possible interactions of antihistamincs and antibiotics with oral contraceptive effectiveness. Fertility and Slenlity 37: 853–854, 1982Google Scholar
  32. Diamond MP, Greene JW, Thompson JM, Vamtooydonk JE, Wentz A. Interaction of anliconv ulsanis and oral contraceptives in epileptic adolescents. Contraception 31: 623–632, 1985PubMedCrossRefGoogle Scholar
  33. Dossetor J. Drug interactions with oral contraceptives. British Medical Journal 4: 467–468, 1975CrossRefGoogle Scholar
  34. Fevcry J, van Stccnncrgen W, Desmet V. Severe intrahepatic cholestasis due to the combined intake of oral contraceptives and triaceiyloleandomycin. Acta Ctinica Belgica 38: 242–245, 1983Google Scholar
  35. Fraser IS, Jansen RPS. Why do inadvertent pregnancies occur in oral contraceptive users? Contraception 27: 531–551, 1983PubMedCrossRefGoogle Scholar
  36. Frey BM, Schard HJ, Frey JF. Pharmacokinetic interaction of contraceptive steroids with Prednisone and prednisolonc. European Journal of Clinical Pharmacology 26: 505–511, 1984PubMedCrossRefGoogle Scholar
  37. Friedman CI, Huneke AL, Kim MH, Powell J. The effect of ampicillm on oral contraceptive effectiveness. Obstetrics and Gvnecology 55: 33–37, 1980Google Scholar
  38. Gagnaire JC, Tchertchian J, Revol A, Rochet Y. Grossesses sous contraceptifs oraux chez les patients recevant des barbituriques. Nouvelle Presse Médicale 4: 3008, 1975PubMedGoogle Scholar
  39. Grimmer SFM, Allen WL, Back DJ, Breckenridge AM, Orme ML’E, et al. The effect of cotrimoxazole on oral contraceptive steroids in women. Contraception 28: 53–59, 1983PubMedCrossRefGoogle Scholar
  40. Grimmer SFM, Back DJ, Orme ML’E, Cowie A, Gilmore I, et al. The bioavailability of clhinyloeslradiol and levonorgestrel in patients with an ileoslomy. Contraception 33: 51–59, 1986PubMedCrossRefGoogle Scholar
  41. Guengench FR. Oxidation of 17α-clhynylestradiol by human liver cytochrome P-450. Molecular Pharmacology 33: 500–508, 1988Google Scholar
  42. Haber I, Hubens H. Cholestatic jaundice after triacetyloleandomycin and oral contraceptives. Acta Gastroentcrologica Belgica 43: 475–482, 1980Google Scholar
  43. Helton ED, Williams MC, Goldzieher JW. Human urinary and liver conjugates of 17α-elhiny loeslradiol. Steroids 27: 851–867, 1976PubMedCrossRefGoogle Scholar
  44. Hempel Von E, Bohm W, Carol W, Klinger W, Meditamentose Enzyminduktion und hormonale Kontrazeption. Zenlrablail fur Gynakologie 95: 1451–1457, 1973Google Scholar
  45. HendrivTreacev S, Wallace SM, Hindmarsh KW, Wvanl GM, Danilkewich A. The effect of acetaminophen administration on its disposition and body stores of sulphate. European Journal of Clinical Pharmacology 30: 273–278, 1986CrossRefGoogle Scholar
  46. Hobbes J, Boutagy J, Shenfield GM. Interactions between ethanol and oral contraceptive steroids. Clinical Pharmacology and Therapeutics 38: 371–380, 1985PubMedCrossRefGoogle Scholar
  47. Janz D, Schmidt D. Antiepileptic drugs and failure of oral contraceptives. Lancet 1: 113, 1974Google Scholar
  48. Jochemsen R, van der Graaff M, Boeijinga JK, Breimer DD. Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. British Journal of Clinical Pharmacology 13: 319–324, 1982PubMedCrossRefGoogle Scholar
  49. Jones MK, Jones BM. Ethanol metabolism in women taking oral contraceptives. Alcoholism: Clinical and Experimental Research 8: 24–28, 1984CrossRefGoogle Scholar
  50. Joshi JV, Joshi LIM, Sankholi GM, Krishna D, Mandclkar A, et al. A study of the interaction of low dose combination oral contraceptive with ampicillin and metronidazole. Contraception 22: 643–652, 1980PubMedCrossRefGoogle Scholar
  51. Joshi JV, Sankholi GM, Shar RS, Joshi UM. Antacid does not reduce the bioavailability of oral contraceptive steroids in women. International Journal of Clinical Pharmacology. Therapeutics and Toxicology 24: 192–195, 1986Google Scholar
  52. Jung-Hoffmann C, Kuhl H. Interaction with pharmacokinelicsof ethinyloestradiol and progestagens contained in oral contraceptives. Contraception 40: 299–312, 1989PubMedCrossRefGoogle Scholar
  53. Jusko WJ. Influence of cigarette smoking on drug metabolism in man. Drug Metabolism Reviews 9: 221–236, 1979PubMedCrossRefGoogle Scholar
  54. Jusko WJ, Schentag JJ, Clark JH, Gardner M, Yurchak A. Enhanced biotransformation of theophylline in marihuana and tobacco smokers. Clinical Pharmacology and Therapeutics 24: 406–410, 1978Google Scholar
  55. Kallio J, Lindberg R, Hulpponen R, lisalo E. Debrisoqume oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio. British Journal of Clinical Pharmacology 26: 791–795, 1988PubMedCrossRefGoogle Scholar
  56. Kanarkowski R, Tornalore KM, D’Ambrosio R, Gardner MJ, Jusko WJ. Pharmacokinetics of single and multiple doses of ethinylestradiol and levonorgestrel in relation to smoking. Clinical Pharmacology and Therapeutics 43: 23–31, 1988PubMedCrossRefGoogle Scholar
  57. Kendall MJ, Qualerman CP, Jack DB, Beeley L. Metoprolol pharmacokinetics and the oral contraceptive pill. British Journal of Clinical Pharmacology 14: 120–122, 1982PubMedCrossRefGoogle Scholar
  58. Kenyon TE. Unplanned pregnancy in an epileptic. British Medical Journal 1: 686–687, 1972PubMedCrossRefGoogle Scholar
  59. Kronbach T, Fischer V, Meyer UA. Cyclosporinc metabolism in human liver: identification of a cytochrome P450III gene family as the major cyclosporine-metabolizingenzyme explains interactions of cyclosporine with other drugs. Clinical Pharmacology and Therapeutics 43: 630–635, 1988PubMedCrossRefGoogle Scholar
  60. Legier UF, Benet LZ. Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives. Clinical Pharmacology and Therapeutics 39: 425–429, 1986CrossRefGoogle Scholar
  61. Leigh DA, Reeves DS, Simmons K, Thomas AL, Wilkinson PJ. Talampicillin: a new derivative of ampicillin. British Medical Journal 2: 1378–1380, 1976CrossRefGoogle Scholar
  62. Levy G, Galinsky R, Lin JH. Pharmacokinetic consequences and toxicologie implications of endogenous cosubstrate depletion. Drug Metabolism Reviews 13: 1009–1020, 1982PubMedCrossRefGoogle Scholar
  63. Lumley CE, Walker SR, Hall GC, Siaunton N, Grob PR. The under-reporting of adverse drug reactions seen in general practice. Pharmaceutical Medicine 1: 205–212, 1986Google Scholar
  64. Maggs JL, Grimmer SFM, Orme ML’E, Breckenridge AM, Park BK, et al. The biliary and urinary metabolites of 3H-17α-ethinyloeslradiol in women. Xenobiotica 13: 421–431, 1983PubMedCrossRefGoogle Scholar
  65. Meffin PJ, Wing LMH, Sallustio BC, Brooks PM. Alterations in prednisolone disposition as a result of oral contraceptive use and dose. British Journal of Clinical Pharmacology 17: 655–664, 1984PubMedCrossRefGoogle Scholar
  66. Michnovicz JJ, Herschcopf RJ, Naganuma H, Bradlow HL, Fishman J. Increased 2-hydroxylation of cslradiol as a possible mechanism for the anti-eslrogcnic effect of cigarette smoking. New England Journal of Medicine 315: 1305–1309, 1986PubMedCrossRefGoogle Scholar
  67. Miners JO, Attwood J, Birken DJ. Influence of sex and oral contraceptive steroids on paracetamol metabolism. British Journal of Clinical Pharmacology 16: 503–509, 1983PubMedCrossRefGoogle Scholar
  68. Miners JOU, Grgurinovich N, Whilchcad AG, Robson RA, Birkett DJ. Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. British Journal of Clinical Pharmacology 22: 135–142, 1986PubMedCrossRefGoogle Scholar
  69. Miners JO, Robson RA, Birkett DJ. Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination. British Journal of Clinical Pharmacology 18: 240–243, 1984PubMedCrossRefGoogle Scholar
  70. Mitchell MC, Hanew T, Meredith CG, Schenker S. Effects of oral contraceptive steroids on acetaminophen metabolism and elimination. Clinical Pharmacology and Therapeutics 34: 48–53, 1983PubMedCrossRefGoogle Scholar
  71. Ochs HR, Grccnblalt DJ, Friedman H, Burstein ES, Locniskar A, et al. Bromazepam pharmaeokinetics: influence of age, gender, oral contraceptives. Cimetidine and Propranolol. Clinical Pharmacology and Therapeutics 41: 562–570, 1987PubMedCrossRefGoogle Scholar
  72. Ochs HR, Grcenblatt DJ, Verburg-Ochs JS, Harmatz JS, Grchl H. Disposition of cloliazepam: influence of age, sex, oral contraceptives, Cimetidine, isoniazid and clhanol. European Journal of Clinical Pharmacology 26: 55–59, 1984PubMedCrossRefGoogle Scholar
  73. Orme ML’E. The clinical pharmacology of oral contraceptive steroids. British Journal of Clinical Pharmacology 14: 31–42, 1982PubMedCrossRefGoogle Scholar
  74. Orme ML’E, Back DJ. Drug interactions with oral contraceptive steroids. Pharmacy International 1: 38–41, 1980Google Scholar
  75. Orme ML’E, Back DJ. Interactions between oral contraceptive steroids and broad spectrum antibiotics. Clinical and Experimental Dermatology 11: 327–331, 1986PubMedCrossRefGoogle Scholar
  76. Orme ML’E, Back DJ, Breckenridgc AM. Clinical pharmaeokinetics of oral contraceptive steroids. Clinical Pharmaeokinetics 8: 95–136, 1983CrossRefGoogle Scholar
  77. Patwardhan RV, Mitchell MC, Johnson RF, Schenker S. Differential effects of oral contraceptive steroids on the metabolism of benzodiazepines. Hepatology 3: 248–253, 1983PubMedCrossRefGoogle Scholar
  78. Prescott LF. Kinetics and metabolism of paracetamol and phenacetin. British Journal of Clinical Pharmacology 10: 291S–298S, 1980PubMedCrossRefGoogle Scholar
  79. Reimers D, Jezek A. Rifampicin und andere Antituberkulostatika bei gleichzeitiger oraler Kontrazeption. Praxis und Klinik der Pneumologie 25: 255–262, 1981Google Scholar
  80. Rietvald EC, Broekman MMM, Houben JJG, Eskes TKAB, van Rossum JM. Rapid onset of an increase in caffeine residence time in young women due to oral contraceptive steroids. European Journal of Clinical Pharmacology 26: 371–373, 1984CrossRefGoogle Scholar
  81. Roberton YR, Johnson ES. Interactions between oral contraceptives and other drugs: a review. Current Medical Research and Opinion 3: 647–661, 1976CrossRefGoogle Scholar
  82. Roberts RK, Desmond PV, Wilkinson GR, Schenker S. Disposition of chlordiazepoxide: sex differences and effects of oral contraceptives. Clinical Pharmacology and Therapeutics 25: 826–831, 1979PubMedGoogle Scholar
  83. Roberts RK, Grice J, McGuffie C, Heilbronn L. Oral contraceptive steroids impair the elimination of thcophyllinc. Journal of Laboratory and Clinical Medicine 101: 821–825, 1983PubMedGoogle Scholar
  84. Robson RA, Matthews AP, Miners JO, McManus ME, Mcyer UA, et al. Characterisation of thcophyllinc metabolism in human liver microsomes. British Journal of Clinical Pharmacology 24: 293–300, 1987PubMedCrossRefGoogle Scholar
  85. Rogers SM, Back DJ, Orme ML’E. Intestinal metabolism of ethinylocslradiol and paracetamol in vitror: studies using Ussing Chambers. British Journal of Clinical Pharmacology 23: 727–734, 1987aPubMedCrossRefGoogle Scholar
  86. Rogers SM, Back DJ, Stevenson PJ, Grimmer SFM, Orme ML’E. Paracetamol interaction with oral contraceptive steroids: increased plasma concentrations of ethinyloestradiol. British Journal of Clinical Pharmacology 23: 721–725, 1987bPubMedCrossRefGoogle Scholar
  87. Sahlberg B-L, Axclson M, Collins DJ, Sjovall J. Analysis of isomeric cthinylestradiol glucuronidcs in urine. Journal of Chromatography 217: 453–461, 1981PubMedCrossRefGoogle Scholar
  88. Shenfield GM. Drug interactions with oral contraceptive preparations. Medical Journal of Australia 144: 205–211, 1986PubMedGoogle Scholar
  89. Sparrow MJ. Pill method failures. New Zealand Medical Journal 100: 102–105, 1987PubMedGoogle Scholar
  90. Stocklcy I. Drug interactions: an appraisal of the current situation. Trends in Pharmacological Sciences 1: 6, 1979CrossRefGoogle Scholar
  91. Stochr GP, Krobath PD, Juhl RP, Wender DB, Phillips JP, et al. Effect of oral contraceptives on triazolam, temazepam, alprazolam and lorazepam kinetics. Clinical Pharmacology and Therapeutics 36: 683–690, 1984CrossRefGoogle Scholar
  92. Szoka PR, Edgren RA. Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database. Fertility and Sterility 49: 31–38S, 1988Google Scholar
  93. Tephly TR, Manncring GT. Inhibition of drug metabolism. V. Inhibition of drug metabolism by steroids. Molecular Pharmacology 4: 10–14, 1968PubMedGoogle Scholar
  94. Van Dijkc CPH, Weber JCP. Interaction between oral contraceptives and griseofulvin. British Medical Journal 288: 1125–1126, 1984Google Scholar
  95. Vestal RE, Cusack BJ, Mercer GD, Dawson GW, Park BK. Aging and drug interactions. I. Effect of Cimetidine and smoking on the oxidation of theophylline and cortisol in healthy men. Journal of Pharmacology and Experimental Therapeutics 241: 488–500, 1987PubMedGoogle Scholar
  96. Vestal RE, Wood AJJ, Branch RA, Shand DG, Wilkinson GR. Effects of age and cigarette smoking on the disposition of Propranolol in man. Clinical Pharmacology and Therapeutics 26: 8–15, 1979PubMedGoogle Scholar
  97. Watson KJR, Ghabrial H, Mashford ML, Harman PJ, Brccn KJ, et al. The oral contraceptive pill increases morphine clearance but docs not increase hepatic blood flow. Gaslroentcrology 90: 1779, 1986Google Scholar
  98. Wood AJJ, Vestcl RE, Wilkinson GR, Branch RA, Shand DG. Effects of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clinical Pharmacology and Therapeutics 26: 16–20, 1979PubMedGoogle Scholar

Copyright information

© Adis Press Limited 1990

Authors and Affiliations

  • David J. Back
    • 1
  • Michael L’E. Orme
    • 1
  1. 1.Department of Pharmacology and TherapeuticsUniversity of LiverpoolLiverpoolEngland

Personalised recommendations